MedPath

Novartis Pharma Stein AG

🇨🇭Switzerland
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

87

PHILIPPINES:33
SFDA:31
NMPA:23

Drug Approvals

Pasireotide Diaspartate Injection

Product Name
丝尼芬
Approval Number
H20150317
Approval Date
Jul 3, 2019
NMPA

Pasireotide Diaspartate Injection

Product Name
丝尼芬
Approval Number
H20150318
Approval Date
Jul 3, 2019
NMPA

Pasireotide Diaspartate Injection

Product Name
丝尼芬
Approval Number
H20150316
Approval Date
Jul 3, 2019
NMPA

Pasireotide Diaspartate Injection

Product Name
丝尼芬
Approval Number
H20150315
Approval Date
Jul 3, 2019
NMPA

Pasireotide Diaspartate Injection

Product Name
丝尼芬
Approval Number
H20150320
Approval Date
Jul 3, 2019
NMPA

Pasireotide Diaspartate Injection

Product Name
丝尼芬
Approval Number
H20150319
Approval Date
Jul 3, 2019
NMPA

Indacaterol Maleate and Glycopyrronium Bromide Powder for Inhalation, Hard Capsules

Product Name
杰润
Approval Number
H20170391
Approval Date
Apr 11, 2019
NMPA

Indacaterol Maleate and Glycopyrronium Bromide Powder for Inhalation, Hard Capsules

Product Name
杰润
Approval Number
H20170390
Approval Date
Apr 11, 2019
NMPA

Glycopyrronium Bromide Powder for Inhalation, Hard Capsules

Product Name
希润
Approval Number
H20180002
Approval Date
Jan 30, 2019
NMPA

Glycopyrronium Bromide Powder for Inhalation, Hard Capsules

Product Name
希润
Approval Number
H20180003
Approval Date
Jan 30, 2019
NMPA
  • Prev
  • 1
  • 2
  • 3
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.